SLC22A16 and acute myeloid leukemia: In AML, rate-limiting enzymes such as carnitine palmitoyl transferase 1a (CPT1a) and carnitine transporter 2 SLC22A16 (CT2) are often overexpressed and are validated therapeutic targets [4].